Claims
- 1. A compound of the formula: ##STR52## wherein X is divalent oxygen or divalent sulfur; R.sub.1 is selected from the group consisting of hydrogen, alkyl (C.sub.1 -C.sub.3), chloro, bromo, iodo and haloalkyl (C.sub.1 -C.sub.3); R.sub.2 is selected from the group consisting of hydrogen, alkyl (C.sub.1 -C.sub.4), cycloalkyl (C.sub.3 -C.sub.6), methoxymethyl, benzyl, naphthyl, phenyl and mono-substituted phenyl wherein said substituent is selected from the group consisting of halo, alkyl (C.sub.1 -C.sub.4), haloalkyl (C.sub.1 -C.sub.3) amino, dialkylamino and nitro; R.sub.3 is selected from the group consisting of hydrogen, alkyl (C.sub.1 -C.sub.3), alkenyl (C.sub.3 -C.sub.4) and alkynyl (C.sub.3 -C.sub.4); R.sub.4 is selected from the group consisting of hydrogen and alkyl (C.sub.1 -C.sub.3).
- 2. The compound according to claim 1 wherein X is oxygen; R.sub.1 is methyl, bromo or chloro; R.sub.2 is cycloalkyl (C.sub.3 -C.sub.6), phenyl or m-tolyl; and R.sub.3 and R.sub.4 are both hydrogen.
- 3. The compound according to claim 1 wherein X is oxygen and R.sub.1 and R.sub.2 are both hydrogen.
- 4. The compound according to claim 1 wherein X is sulfur and R.sub.1 and R.sub.2 are both hydrogen.
- 5. The compound according to claim 1 wherein X is oxygen, R.sub.1 is methyl, and R.sub.2 is phenyl.
- 6. The compound according to claim 1 wherein X is sulfur, R.sub.1 is methyl, and R.sub.2 is phenyl.
- 7. The compound according to claim 1 wherein X is oxygen and R.sub.1 and R.sub.2 are both methyl.
- 8. The compound according to claim 1 wherein X is sulfur and R.sub.1 and R.sub.2 are both methyl.
- 9. The compound according to claim 1 wherein X is oxygen, R.sub.1 is bromo, and R.sub.2 is phenyl.
- 10. The compound according to claim 1 wherein X is sulfur, R.sub.1 is methyl, and R.sub.2 is benzyl.
- 11. The compound according to claim 1 wherein X is oxygen, R.sub.1 is chloro and R.sub.2 is phenyl.
- 12. The compound according to claim 1 wherein X is oxygen, R.sub.1 and R.sub.3 are both methyl, and R.sub.2 is phenyl.
- 13. The compound according to claim 1 wherein X is oxygen, R.sub.1 is methyl and R.sub.2 is n-propyl.
- 14. The compound according to claim 1 wherein X is oxygen, R.sub.1 is methyl, and R.sub.2 is tert-butyl.
- 15. The compound according to claim 1 wherein X is oxygen, R.sub.1 is chloro, and R.sub.2 is p-chlorophenyl.
- 16. The compound according to claim 1 wherein X is oxygen, R.sub.1 is methyl, and R.sub.2 is cyclohexyl.
- 17. The compound according to claim 1 wherein X is oxygen, R.sub.1 is methyl, and R.sub.2 is m-tolyl.
- 18. The compound according to claim 1 wherein X is oxygen, R.sub.1 is iodo, and R.sub.2 is phenyl.
- 19. The compound according to claim 1 wherein X is oxygen, R.sub.1 is methyl and R.sub.2 is p-aminophenyl.
- 20. The compound according to claim 1 wherein X is oxygen, R.sub.1 is bromo, and R.sub.2 is m-dimethylaminophenyl.
- 21. The compound according to claim 1 wherein R.sub.1 is methyl and R.sub.2 is 2-naphthyl.
- 22. A method of inhibiting the enzyme phosphodiesterase in a mammal which comprises administering internally to said mammal an effective amount of a compound of the formula: ##STR53## wherein X is divalent oxygen or divalent sulfur; R.sub.1 is selected from the group consisting of hydrogen, chloro, bromo and alkyl having up to 3 carbon atoms; and R.sub.2 is selected from the group consisting of hydrogen, alkyl having up to 4 carbon atoms, phenyl, benzyl, methoxymethyl and o-propoxyphenyl.
- 23. A therapeutic composition in dosage unit form useful for inhibiting the enzyme phosphodisterase in mammals comprising from about 1.0 mg. to about 25.0 mg. per kg. of body weight per daily dosage unit, in association with a pharmaceutical carrier, of a compound of that formula: ##STR54## wherein X is divalent oxygen or divalent sulfur; R.sub.1 is selected from the group consisting of hydrogen, chloro, bromo and alkyl having up to 3 carbon atoms, and R.sub.2 is selected from the group consisting of hydrogen, alkyl having up to 4 carbon atoms, phenyl, benzyl, methoxymethyl and o-propoxyphenyl.
- 24. The process of preparing compounds of the formula: ##STR55## wherein R.sub.1 is hydrogen or alkyl having up to 3 carbon atoms and R.sub.2 is hydrogen, alkyl having up to 4 carbon atoms, phenyl, benzyl, methoxymethyl or o-propoxyphenyl which comprises heating a compound of the formula: ##STR56## wherein R is methyl or ethyl and R.sub.1 and R.sub.2 are as hereinabove defined in a non-polar high boiling organic solvent at a temperature of 175.degree.-275.degree. C. for a period of time sufficient for a substantial degree of ring closure to occur.
- 25. The process of preparing compounds of the formula: ##STR57## wherein R.sub.1 is hydrogen or alkyl having up to 3 carbon atoms and R.sub.2 is hydrogen, alkyl having up to 4 carbon atoms, phenyl, benzyl, methoxymethyl or o-propoxypheyl which comprises heating a compound of the formula: ##STR58## wherein R is methyl or ethyl and R.sub.1 and R.sub.2 are as hereinabove defined in a non-polar high boiling organic solvent at a temperature of 175.degree.-275.degree. C. for a period of time sufficient for a substantial degree of ring closure to occur.
- 26. The process of preparing compounds of the formula: ##STR59## wherein X is divalent oxygen or divalent sulfur; R.sub.1 is chloro or bromo; and R.sub.2 is hydrogen, alkyl having up to 4 carbon atoms, phenyl, benzyl, methoxymethyl or o-propoxyphenyl which comprises treating a compound of the formula: ##STR60## wherein X and R.sub.2 are as hereinabove defined with chlorine or bromine in an inert solvent at a temperature of 60.degree.-90.degree. C. for a period of time sufficient for a substantial degree of halogenation to occur.
- 27. The process of preparing compounds of the formula: ##STR61## wherein R.sub.1 is hydrogren, chloro, bromo or alkyl having up to 3 carbon atoms and R.sub.2 is hydrogen, alkyl having up to 4 carbon atoms, phenyl, benzyl, methoxymethyl or o-propoxyphenyl which comprises treating a compound of the formula: ##STR62## wherein R.sub.1 and R.sub.2 are as hereinabove defined with phosphorus pentasulfide in an inert solvent at a temperature of 100.degree.-150.degree. C. for a period of time sufficient for a substantial degree of replacement to occur.
Parent Case Info
This application is a continuation-in-part application of our copending application, Ser. No. 765,318, filed Feb. 3, 1977, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
2837520 |
Fusco et al. |
Jun 1958 |
|
3840537 |
Garside et al. |
Oct 1974 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
765318 |
Feb 1977 |
|